Výsledky vyhledávání - Susan Feyerabend

  • Zobrazuji výsledky 1 - 17 z 17
Upřesnit hledání
  1. 1
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24... Autor Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliott, Enrique Grande, Amal Melhem‐Bertrandt, Benoît Baron, Mohammad Hirmand, Patrick Werbrouck, Karim Fizazi

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas

    Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas Autor Sebastian Attig, Jörg Hennenlotter, Graham Pawelec, Gerd Klein, Sven D. Koch, Hanspeter Pircher, Susan Feyerabend, Dorothee Wernet, Arnulf Stenzl, Hans‐Georg Rammensee, Cécile Gouttefangeas

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

    Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A networ... Autor Susan Feyerabend, Fred Saad, Tracy Li, Tetsuro Ito, Joris Diels, Suzy Van Sanden, Peter De Porre, Julie Roïz, Ṣẹ̀yẹ Abògúnr̀in, Maria Koufopoulou, Karim Fizazi

    Vydáno 2018
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Promiscuous survivin peptide induces robust CD4<sup>+</sup> T‐cell responses in the majority of vaccinated cancer patients

    Promiscuous survivin peptide induces robust CD4<sup>+</sup> T‐cell responses in the majority of vaccinated cancer patients Autor Melanie Widenmeyer, Heinrich Griesemann, Stefan Stevanović, Susan Feyerabend, Reinhild Klein, Sebastian Attig, Jörg Hennenlotter, Dorothee Wernet, Dmitry V. Kuprash, Alexei Y. Sazykin, Steve Pascolo, Arnulf Stenzl, Cécile Gouttefangeas, Hans‐Georg Rammensee

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Autor Gerhardt Attard, Axel S. Merseburger, Wiebke Arlt, Cora N. Sternberg, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Lajos Géczi, Florence Lefresne, Marjolein Lahaye, Florence Nave Shelby, Geneviève Pissart, Sue Chua, Robert J. Jones, Bertrand Tombal

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

    Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a rand... Autor Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Giri Sulur, Yesenia Luna, Susan Li, Suneel Mundle, Kim N.

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

    Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry Autor Simon Chowdhury, Anders Bjartell, Nicolaas Lumen, Pablo Maroto, Thomas Paiss, F. Gómez-Veiga, Alison Birtle, Gero Kramer, Ewa Kalinka‐Warzocha, Dominique Spaëth, Susan Feyerabend, Vsevolod Matveev, Florence Lefresne, Martin Lukáč, Robert Wapenaar, Luís Costa

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

    Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Autor Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, B. Yа. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre, Thian Kheoh, Youn C. Park, Mary B. Todd, Kim N.

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

    Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer Autor Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean‐Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Daniel Castellano

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

    Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) Autor Petros Grivas, Yohann Loriot, Rafael Morales‐Barrera, Min Yuen Teo, Yousef Zakharia, Susan Feyerabend, Nicholas J. Vogelzang, Enrique Grande, Nabil Adra, Ajjai Alva, Andrea Necchi, Alejo Rodríguez‐Vida, Sumati Gupta, Debra H. Josephs, S. Srinivas, Kenton Wride, Daleen Thomas, Andrew D. Simmons, Andrea Loehr, Rachel L. Dusek, Dale Nepert, S. Chowdhury

    Vydáno 2021
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

    Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre... Autor Karim Fizazi, Gero Kramer, Jean-Christophe Eymard, Cora N. Sternberg, Johann S. de Bono, Daniel Castellano, Bertrand Tombal, Christian Wülfing, Michalis Liontos, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Théodore, Susan Feyerabend, Carole Hélissey, Stéphane Oudard, Gaetano Facchini, Elizabeth M. Poole, Ayse Ӧzatılgan, Christine Geffriaud-Ricouard, Samira Bensfia, Ronald de Wit

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

    Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study Autor Guilhem Roubaud, Mustafa Özgüroğlu, Nicolas Penel, Nobuaki Matsubara, Niven Mehra, Michael Paul Kolinsky, Giuseppe Procopio, Susan Feyerabend, Jae Young Joung, Gwénaëlle Gravis, Kazuo Nishimura, Craig Gedye, Charles Padua, Neal D. Shore, Antoine Thiery-Vuillemin, Fred Saad, Robbert van Alphen, Michael A. Carducci, Chintu Desai, Neil Brickel, Christian Poehlein, Paula del Rosario, Karim Fizazi

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

    Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study Autor Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Kristiina Ojamaa, Christopher Hoimes, Ulka N. Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann S. de Bono

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 Autor Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Bögemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houédé, Syed A. Hussain, Elaine T. Lam, Jonathan Polikoff, Arnulf Stenzl, Paul N. Mainwaring, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS Autor Neal D. Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L.J. Tammela, David Morris, Jeanny B. Aragon‐Ching, Raoul S. Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, V. Lietuvietis, Hakim Mahammedi, Francisco Cruz, Adriano Augusto Peclat de Paula, Christopher Pieczonka, Antti Rannikko, Martin Eduardo Richardet, Glauco Costa Silveira, Iris Kuss, Marie‐Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew Ryan Smith, Karim Fizazi

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

    Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer Autor Nicholas J. Vogelzang, Tomasz M. Beer, Winald R. Gerritsen, Stéphane Oudard, Paweł Wiechno, Bożena Kukiełka-Budny, Vladimír Šámal, Jaroslav Hájek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csőszi, Zoran Filipovic, Frederico Gonçalves, А А Прохоров, Eric Cheung, Arif Hussain, Nuno Sousa, Amit Bahl, Syed A. Hussain, Harald Fricke, Pavla Kadlecová, Tomáš Scheiner, Roman Korolkiewicz, Jiřina Bartůňková, Radek Špíšek, Walter M. Stadler, Arthur Berg, Karl‐Heinz Kurth, Celestia S. Higano, Matti Aapro, Michael Krainer, Stephan Hruby, Johannes Meran, S. Polyakov, Jean‐Pascal Machiels, Thierry Roumeguère, Koen Ackaert, Nicolaas Lumen, Thierry Gil, Velko Minchev, Antoaneta Tomova, Borislav D. Dimitrov, Marchela Koleva, Antonio Juretić, Ana Fröbe, Željko Vojnović, Martin Drabek, L. Jarolím, Tomáš Büchler, Eva Kindlová, Jan Schraml, Milada Zemanová, Prausova Jana, Bohuslav Melichar, Martina Chodacká, Jan Jansa, Gedske Daugaard, Nicolas Delonchamps, Brigitte Duclos, Stéphane Culine, G. Deplanque, Sylvestre Le Moulec, Peter Hammerer, Gerald Rodemer, Manuel Ritter, Axel S. Merseburger, Marc‐Oliver Grimm, Ilija Damjanoski, Manfred Wirth, Martin Burmester, Kurt Miller, Jan Herden, Bastian Keck, Christian Wuelfing, Alexander Winter, Martin Boegemann, Ingo Kausch von Schmeling, Paolo Fornara, E. Jaeger, G. Bodoky, Zsuzsanna Pápai, Géza Böszörményi-Nagy, Paola Vanella, Héctor Soto Parrà, Rodolfo Passalacqua, Francesco Ferraù, Michele Maio, Lucia Fratino, Enrico Cortesi, Gunta Purkalne, Jolita Asadauskienė, Rasa Jančiauskienė, Skaistė Tulytė, Alvydas Česas, Marco B. Polée, Brigitte C. M. Haberkorn, Fons van de Eertwegh, Pieter van den Berg, Aart Beeker

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Autor Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Peter Francis, George Wang, Daphne Wu, Brooke Diorio, Angela Lopez‐Gitlitz, Shahneen Sandhu, María Alejandra Álvarez, Gabriela Gatica, Martín Greco, Ernesto Korbenfeld, Esteban Metrebián, Jorge Salinas, Alejandro Salvatierra, Marcelo Tatangelo, Tom Ferguson, Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Yong-Lian Guo, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon, Ian Sayers

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: